CareDx (CDNA)
(Real Time Quote from BATS)
$29.37 USD
-0.75 (-2.49%)
Updated Sep 18, 2024 01:32 PM ET
2-Buy of 5 2
F Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
CDNA 29.37 -0.75(-2.49%)
Will CDNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CDNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDNA
Community Health's Arm Northwest Urgent Buys 10 Arizona Facilities
Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?
CDNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
Other News for CDNA
Wall Street Lunch: Intel Grabs Wall Street Attention
CareDx Inc (CDNA) Stock Price Up 4.41% on Sep 17
Small-cap stocks have climbed recently. Here are the ones most poised for further upside
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)